Journal of Clinical and Diagnostic Research, ISSN - 0973 - 709X

Users Online : 125506

AbstractCase ReportDiscussionConclusionReferencesDOI and Others
Article in PDF How to Cite Citation Manager Readers' Comments (0) Audio Visual Article Statistics Link to PUBMED Print this Article Send to a Friend
Advertisers Access Statistics Resources

Dr Mohan Z Mani

"Thank you very much for having published my article in record time.I would like to compliment you and your entire staff for your promptness, courtesy, and willingness to be customer friendly, which is quite unusual.I was given your reference by a colleague in pathology,and was able to directly phone your editorial office for clarifications.I would particularly like to thank the publication managers and the Assistant Editor who were following up my article. I would also like to thank you for adjusting the money I paid initially into payment for my modified article,and refunding the balance.
I wish all success to your journal and look forward to sending you any suitable similar article in future"

Dr Mohan Z Mani,
Professor & Head,
Department of Dermatolgy,
Believers Church Medical College,
Thiruvalla, Kerala
On Sep 2018

Prof. Somashekhar Nimbalkar

"Over the last few years, we have published our research regularly in Journal of Clinical and Diagnostic Research. Having published in more than 20 high impact journals over the last five years including several high impact ones and reviewing articles for even more journals across my fields of interest, we value our published work in JCDR for their high standards in publishing scientific articles. The ease of submission, the rapid reviews in under a month, the high quality of their reviewers and keen attention to the final process of proofs and publication, ensure that there are no mistakes in the final article. We have been asked clarifications on several occasions and have been happy to provide them and it exemplifies the commitment to quality of the team at JCDR."

Prof. Somashekhar Nimbalkar
Head, Department of Pediatrics, Pramukhswami Medical College, Karamsad
Chairman, Research Group, Charutar Arogya Mandal, Karamsad
National Joint Coordinator - Advanced IAP NNF NRP Program
Ex-Member, Governing Body, National Neonatology Forum, New Delhi
Ex-President - National Neonatology Forum Gujarat State Chapter
Department of Pediatrics, Pramukhswami Medical College, Karamsad, Anand, Gujarat.
On Sep 2018

Dr. Kalyani R

"Journal of Clinical and Diagnostic Research is at present a well-known Indian originated scientific journal which started with a humble beginning. I have been associated with this journal since many years. I appreciate the Editor, Dr. Hemant Jain, for his constant effort in bringing up this journal to the present status right from the scratch. The journal is multidisciplinary. It encourages in publishing the scientific articles from postgraduates and also the beginners who start their career. At the same time the journal also caters for the high quality articles from specialty and super-specialty researchers. Hence it provides a platform for the scientist and researchers to publish. The other aspect of it is, the readers get the information regarding the most recent developments in science which can be used for teaching, research, treating patients and to some extent take preventive measures against certain diseases. The journal is contributing immensely to the society at national and international level."

Dr Kalyani R
Professor and Head
Department of Pathology
Sri Devaraj Urs Medical College
Sri Devaraj Urs Academy of Higher Education and Research , Kolar, Karnataka
On Sep 2018

Dr. Saumya Navit

"As a peer-reviewed journal, the Journal of Clinical and Diagnostic Research provides an opportunity to researchers, scientists and budding professionals to explore the developments in the field of medicine and dentistry and their varied specialities, thus extending our view on biological diversities of living species in relation to medicine.
‘Knowledge is treasure of a wise man.’ The free access of this journal provides an immense scope of learning for the both the old and the young in field of medicine and dentistry as well. The multidisciplinary nature of the journal makes it a better platform to absorb all that is being researched and developed. The publication process is systematic and professional. Online submission, publication and peer reviewing makes it a user-friendly journal.
As an experienced dentist and an academician, I proudly recommend this journal to the dental fraternity as a good quality open access platform for rapid communication of their cutting-edge research progress and discovery.
I wish JCDR a great success and I hope that journal will soar higher with the passing time."

Dr Saumya Navit
Professor and Head
Department of Pediatric Dentistry
Saraswati Dental College
On Sep 2018

Dr. Arunava Biswas

"My sincere attachment with JCDR as an author as well as reviewer is a learning experience . Their systematic approach in publication of article in various categories is really praiseworthy.
Their prompt and timely response to review's query and the manner in which they have set the reviewing process helps in extracting the best possible scientific writings for publication.
It's a honour and pride to be a part of the JCDR team. My very best wishes to JCDR and hope it will sparkle up above the sky as a high indexed journal in near future."

Dr. Arunava Biswas
MD, DM (Clinical Pharmacology)
Assistant Professor
Department of Pharmacology
Calcutta National Medical College & Hospital , Kolkata

Dr. C.S. Ramesh Babu
" Journal of Clinical and Diagnostic Research (JCDR) is a multi-specialty medical and dental journal publishing high quality research articles in almost all branches of medicine. The quality of printing of figures and tables is excellent and comparable to any International journal. An added advantage is nominal publication charges and monthly issue of the journal and more chances of an article being accepted for publication. Moreover being a multi-specialty journal an article concerning a particular specialty has a wider reach of readers of other related specialties also. As an author and reviewer for several years I find this Journal most suitable and highly recommend this Journal."
Best regards,
C.S. Ramesh Babu,
Associate Professor of Anatomy,
Muzaffarnagar Medical College,
On Aug 2018

Dr. Arundhathi. S
"Journal of Clinical and Diagnostic Research (JCDR) is a reputed peer reviewed journal and is constantly involved in publishing high quality research articles related to medicine. Its been a great pleasure to be associated with this esteemed journal as a reviewer and as an author for a couple of years. The editorial board consists of many dedicated and reputed experts as its members and they are doing an appreciable work in guiding budding researchers. JCDR is doing a commendable job in scientific research by promoting excellent quality research & review articles and case reports & series. The reviewers provide appropriate suggestions that improve the quality of articles. I strongly recommend my fraternity to encourage JCDR by contributing their valuable research work in this widely accepted, user friendly journal. I hope my collaboration with JCDR will continue for a long time".

Dr. Arundhathi. S
MBBS, MD (Pathology),
Sanjay Gandhi institute of trauma and orthopedics,
On Aug 2018

Dr. Mamta Gupta,
"It gives me great pleasure to be associated with JCDR, since last 2-3 years. Since then I have authored, co-authored and reviewed about 25 articles in JCDR. I thank JCDR for giving me an opportunity to improve my own skills as an author and a reviewer.
It 's a multispecialty journal, publishing high quality articles. It gives a platform to the authors to publish their research work which can be available for everyone across the globe to read. The best thing about JCDR is that the full articles of all medical specialties are available as pdf/html for reading free of cost or without institutional subscription, which is not there for other journals. For those who have problem in writing manuscript or do statistical work, JCDR comes for their rescue.
The journal has a monthly publication and the articles are published quite fast. In time compared to other journals. The on-line first publication is also a great advantage and facility to review one's own articles before going to print. The response to any query and permission if required, is quite fast; this is quite commendable. I have a very good experience about seeking quick permission for quoting a photograph (Fig.) from a JCDR article for my chapter authored in an E book. I never thought it would be so easy. No hassles.
Reviewing articles is no less a pain staking process and requires in depth perception, knowledge about the topic for review. It requires time and concentration, yet I enjoy doing it. The JCDR website especially for the reviewers is quite user friendly. My suggestions for improving the journal is, more strict review process, so that only high quality articles are published. I find a a good number of articles in Obst. Gynae, hence, a new journal for this specialty titled JCDR-OG can be started. May be a bimonthly or quarterly publication to begin with. Only selected articles should find a place in it.
An yearly reward for the best article authored can also incentivize the authors. Though the process of finding the best article will be not be very easy. I do not know how reviewing process can be improved. If an article is being reviewed by two reviewers, then opinion of one can be communicated to the other or the final opinion of the editor can be communicated to the reviewer if requested for. This will help one’s reviewing skills.
My best wishes to Dr. Hemant Jain and all the editorial staff of JCDR for their untiring efforts to bring out this journal. I strongly recommend medical fraternity to publish their valuable research work in this esteemed journal, JCDR".

Dr. Mamta Gupta
(Ex HOD Obs &Gynae, Hindu Rao Hospital and associated NDMC Medical College, Delhi)
Aug 2018

Dr. Rajendra Kumar Ghritlaharey

"I wish to thank Dr. Hemant Jain, Editor-in-Chief Journal of Clinical and Diagnostic Research (JCDR), for asking me to write up few words.
Writing is the representation of language in a textual medium i e; into the words and sentences on paper. Quality medical manuscript writing in particular, demands not only a high-quality research, but also requires accurate and concise communication of findings and conclusions, with adherence to particular journal guidelines. In medical field whether working in teaching, private, or in corporate institution, everyone wants to excel in his / her own field and get recognised by making manuscripts publication.

Authors are the souls of any journal, and deserve much respect. To publish a journal manuscripts are needed from authors. Authors have a great responsibility for producing facts of their work in terms of number and results truthfully and an individual honesty is expected from authors in this regards. Both ways its true "No authors-No manuscripts-No journals" and "No journals–No manuscripts–No authors". Reviewing a manuscript is also a very responsible and important task of any peer-reviewed journal and to be taken seriously. It needs knowledge on the subject, sincerity, honesty and determination. Although the process of reviewing a manuscript is a time consuming task butit is expected to give one's best remarks within the time frame of the journal.
Salient features of the JCDR: It is a biomedical, multidisciplinary (including all medical and dental specialities), e-journal, with wide scope and extensive author support. At the same time, a free text of manuscript is available in HTML and PDF format. There is fast growing authorship and readership with JCDR as this can be judged by the number of articles published in it i e; in Feb 2007 of its first issue, it contained 5 articles only, and now in its recent volume published in April 2011, it contained 67 manuscripts. This e-journal is fulfilling the commitments and objectives sincerely, (as stated by Editor-in-chief in his preface to first edition) i e; to encourage physicians through the internet, especially from the developing countries who witness a spectrum of disease and acquire a wealth of knowledge to publish their experiences to benefit the medical community in patients care. I also feel that many of us have work of substance, newer ideas, adequate clinical materials but poor in medical writing and hesitation to submit the work and need help. JCDR provides authors help in this regards.
Timely publication of journal: Publication of manuscripts and bringing out the issue in time is one of the positive aspects of JCDR and is possible with strong support team in terms of peer reviewers, proof reading, language check, computer operators, etc. This is one of the great reasons for authors to submit their work with JCDR. Another best part of JCDR is "Online first Publications" facilities available for the authors. This facility not only provides the prompt publications of the manuscripts but at the same time also early availability of the manuscripts for the readers.
Indexation and online availability: Indexation transforms the journal in some sense from its local ownership to the worldwide professional community and to the public.JCDR is indexed with Embase & EMbiology, Google Scholar, Index Copernicus, Chemical Abstracts Service, Journal seek Database, Indian Science Abstracts, to name few of them. Manuscriptspublished in JCDR are available on major search engines ie; google, yahoo, msn.
In the era of fast growing newer technologies, and in computer and internet friendly environment the manuscripts preparation, submission, review, revision, etc and all can be done and checked with a click from all corer of the world, at any time. Of course there is always a scope for improvement in every field and none is perfect. To progress, one needs to identify the areas of one's weakness and to strengthen them.
It is well said that "happy beginning is half done" and it fits perfectly with JCDR. It has grown considerably and I feel it has already grown up from its infancy to adolescence, achieving the status of standard online e-journal form Indian continent since its inception in Feb 2007. This had been made possible due to the efforts and the hard work put in it. The way the JCDR is improving with every new volume, with good quality original manuscripts, makes it a quality journal for readers. I must thank and congratulate Dr Hemant Jain, Editor-in-Chief JCDR and his team for their sincere efforts, dedication, and determination for making JCDR a fast growing journal.
Every one of us: authors, reviewers, editors, and publisher are responsible for enhancing the stature of the journal. I wish for a great success for JCDR."

Thanking you
With sincere regards
Dr. Rajendra Kumar Ghritlaharey, M.S., M. Ch., FAIS
Associate Professor,
Department of Paediatric Surgery, Gandhi Medical College & Associated
Kamla Nehru & Hamidia Hospitals Bhopal, Madhya Pradesh 462 001 (India)
On May 11,2011

Dr. Shankar P.R.

"On looking back through my Gmail archives after being requested by the journal to write a short editorial about my experiences of publishing with the Journal of Clinical and Diagnostic Research (JCDR), I came across an e-mail from Dr. Hemant Jain, Editor, in March 2007, which introduced the new electronic journal. The main features of the journal which were outlined in the e-mail were extensive author support, cash rewards, the peer review process, and other salient features of the journal.
Over a span of over four years, we (I and my colleagues) have published around 25 articles in the journal. In this editorial, I plan to briefly discuss my experiences of publishing with JCDR and the strengths of the journal and to finally address the areas for improvement.
My experiences of publishing with JCDR: Overall, my experiences of publishing withJCDR have been positive. The best point about the journal is that it responds to queries from the author. This may seem to be simple and not too much to ask for, but unfortunately, many journals in the subcontinent and from many developing countries do not respond or they respond with a long delay to the queries from the authors 1. The reasons could be many, including lack of optimal secretarial and other support. Another problem with many journals is the slowness of the review process. Editorial processing and peer review can take anywhere between a year to two years with some journals. Also, some journals do not keep the contributors informed about the progress of the review process. Due to the long review process, the articles can lose their relevance and topicality. A major benefit with JCDR is the timeliness and promptness of its response. In Dr Jain's e-mail which was sent to me in 2007, before the introduction of the Pre-publishing system, he had stated that he had received my submission and that he would get back to me within seven days and he did!
Most of the manuscripts are published within 3 to 4 months of their submission if they are found to be suitable after the review process. JCDR is published bimonthly and the accepted articles were usually published in the next issue. Recently, due to the increased volume of the submissions, the review process has become slower and it ?? Section can take from 4 to 6 months for the articles to be reviewed. The journal has an extensive author support system and it has recently introduced a paid expedited review process. The journal also mentions the average time for processing the manuscript under different submission systems - regular submission and expedited review.
Strengths of the journal: The journal has an online first facility in which the accepted manuscripts may be published on the website before being included in a regular issue of the journal. This cuts down the time between their acceptance and the publication. The journal is indexed in many databases, though not in PubMed. The editorial board should now take steps to index the journal in PubMed. The journal has a system of notifying readers through e-mail when a new issue is released. Also, the articles are available in both the HTML and the PDF formats. I especially like the new and colorful page format of the journal. Also, the access statistics of the articles are available. The prepublication and the manuscript tracking system are also helpful for the authors.
Areas for improvement: In certain cases, I felt that the peer review process of the manuscripts was not up to international standards and that it should be strengthened. Also, the number of manuscripts in an issue is high and it may be difficult for readers to go through all of them. The journal can consider tightening of the peer review process and increasing the quality standards for the acceptance of the manuscripts. I faced occasional problems with the online manuscript submission (Pre-publishing) system, which have to be addressed.
Overall, the publishing process with JCDR has been smooth, quick and relatively hassle free and I can recommend other authors to consider the journal as an outlet for their work."

Dr. P. Ravi Shankar
KIST Medical College, P.O. Box 14142, Kathmandu, Nepal.
On April 2011

Dear team JCDR, I would like to thank you for the very professional and polite service provided by everyone at JCDR. While i have been in the field of writing and editing for sometime, this has been my first attempt in publishing a scientific paper.Thank you for hand-holding me through the process.

Dr. Anuradha
On Jan 2020

Important Notice

Case Series
Year : 2023 | Month : November | Volume : 17 | Issue : 11 | Page : WR01 - WR04 Full Version

Single Dose of Etanercept Injection: A Game Changer in Toxic Epidermal Necrolysis: A Case Series

Published: November 1, 2023 | DOI:
Rajkumar Kannan, Samuel Jeyaraj Daniel, Parimalam Kumar, Lavanya Kavimani

1. Professor, Department of Dermatology, Venereology and Leprosy (DVL), MMC & RGGH, Chennai, Tamil Nadu, India. 2. Associate Professor, Department of Dermatology, Venereology and Leprosy (DVL), MMC & RGGH, Chennai, Tamil Nadu, India. 3. Professor, Department of Dermatology, Venereology and Leprosy (DVL), MMC & RGGH, Chennai, Tamil Nadu, India. 4. Senior Resident, Department of Dermatology, Venereology and Leprosy (DVL), MMC & RGGGH, Chennai, Tamil Nadu, India.

Correspondence Address :
Dr. Lavanya Kavimani,
Department of Dermatology, Venereology and Leprosy (DVL), Rajiv Gandhi Hospital, Parktown, Chennai-03, Tamil Nadu, India.


Toxic Epidermal Necrolysis (TEN) is a rare hypersensitivity reaction to drugs, characterised by widespread erythema, full-thickness epidermal necrosis with mucosal involvement, and extensive apoptosis. It is a dermatological emergency and can be lethal if not promptly treated. The use of steroids in managing TEN is controversial since no gold standard therapy exists. However, a single dose of subcutaneous injection of Etanercept (a Tumour Necrosis Factor-alpha (TNF-α) inhibitor) at a dosage of 50 mg has shown promise in preventing mortality and reducing hospital stay. The authors present a case series of six TEN patients, out of which three received a single dose of Etanercept injection. All patients who received Etanercept showed a positive response, achieving complete re-epithelialisation with a median healing time of nine days. In conclusion, injection of Etanercept, a TNF-α inhibitor, effectively inhibits Fas-Fas ligand activation, thus preventing apoptosis and extensive necrosis.


Adverse drug reaction, Apoptosis, Repithelialisation, Tumor necrosis factor-α inhibitors

Toxic Epidermal Necrolysis (TEN) is a rare hypersensitivity reaction to drugs, considered a dermatological emergency. It is clinically characterised by widespread erythema, full-thickness epidermal necrosis with mucosal involvement, and extensive apoptosis. The pathogenesis of TEN remains unclear. However, several observations support a role for T-cell mediated immune responses in its development: faster and more severe recurrence of TEN upon re-exposure to the same offending drug, presence of drug-specific T-cells in the skin of TEN patients, and increased risk of developing TEN in individuals with specific Human Leukocyte Antigen (HLA) haplotypes when exposed to certain drugs (1),(2). Etanercept, a TNF-α inhibitor, has a shorter half-life compared to infliximab and adalimumab. In this case series, the authors describe six TEN patients, of whom three received a single dose of Etanercept injection.

Case Report

Case 1

A 27-year-old female with no co-morbidities presented at the Department of Dermatology with a 2-day history of fever and diffuse painful erythematous rashes all over her body. Thirteen days prior to the symptoms, the patient had taken Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) over the counter for joint pain. At the time of presentation, the patient was afebrile but tachycardic, with a pulse rate of 120/min and a blood pressure of 110/70 mm Hg. Physical examination revealed multiple areas of tender, poorly demarcated erythematous to dusky macules, blisters, and extensive skin detachment involving 70% of the Body Surface Area (Table/Fig 1). The oral cavity showed painful erosions and crusting (Table/Fig 1). The Pseudo Nikolsky sign was positive. A Tzanck smear was performed, which showed necrotic basal cells. Laboratory studies were within normal limits. As TEN is a clinical diagnosis, the SCORTEN value was calculated and found to be three. The patient was started on intramuscular injection of Dexamethasone 2 cc and continued on a maintenance dose of oral steroids, gradually tapering by 5 mg every week. On the second day of admission, the patient developed steroid-induced hyperglycaemia. After adequate titration with insulin and obtaining consent, a single subcutaneous dose of injection Etanercept 50 mg was administered. The patient responded well to the treatment, achieving complete re-epithelialisation on day 8 (Table/Fig 2). There were no major complications or side effects post-injection. The patient is currently under follow-up.

Case 2

A 45-year-old female, a known case of systemic hypertension, presented with multiple hypopigmented patches, and after appropriate investigations (positive Slit skin smear with confirmatory histopathological findings), she was diagnosed with Hansen’s disease. She was initiated on Multi Bacillary Multi Drug Therapy (MB-MDT). On the second day of treatment with MB-MDT, the patient developed a painful rash that started on her upper back and spread to cover her entire trunk. Dermatological examination revealed tenderness, an erythematous to dusky macular eruption with multiple erosions and skin peeling, exhibiting a bizarre shape with a positive pseudo -Nikolsky sign on the upper back (Table/Fig 3). The detachment affected 40% of the Body Surface Area (BSA). Laboratory investigations were within normal limits, except for a white cell count of 21,000/cm3 and elevated Liver Function Test (LFT) levels. The diagnosis of Toxic Epidermal Necrolysis (TEN) was made, with a SCORTEN value of three. On the third day of admission, the patient received a single subcutaneous dose of injection Etanercept 50 mg, and she responded well to the treatment. She is currently under regular follow-up.

Case 3

A 30-year-old female, known to have epilepsy, switched her medication from levetiracetam to phenytoin. She subsequently developed erythema, a rash, and skin peeling affecting 90% of the Body Surface Area (BSA) (Table/Fig 4). Laboratory investigations revealed elevated levels of C-Reactive Protein (CRP) (110), LDH (1056), and liver enzymes (SGOT 1067, SGPT 789). The SCORTEN value was 2. On the third day of admission, the patient received a single subcutaneous dose of injection Etanercept 50 mg. After seven days, the patient recovered, and on follow-up (Table/Fig 5).

Case 4

A 68-year-old male was brought to the casualty department in an unresponsive state, exhibiting severe peeling of the skin involving the entire body with mucosal involvement. The patient had fever two days prior and received an injection of ceftriaxone at a nearby hospital. Eight hours after receiving the injection, the patient developed erythema and skin peeling, starting on the face and progressing to involve more than 70% of the Body Surface Area (BSA). The diagnosis was severe cutaneous adverse drug reaction to ceftriaxone (Table/Fig 6). The SCORTEN value was 3. The patient was initiated on intramuscular injection of Dexamethasone 8 mg. Unfortunately, the patient went into cardiac arrest due to sepsis before receiving injection Etanercept.

Case 5

An 11-year-old female child developed Toxic Epidermal Necrolysis (TEN) with involvement of more than 90% of the Body Surface Area (BSA) on the third day of starting Phenytoin, which was given for febrile seizures (Table/Fig 7). The SCORTEN value was 3. The patient was treated with a single injection of Dexamethasone 8 mg as the only available treatment option. Unfortunately, Injection Etanercept could not be given due to its non-availability. On the twelfth day, the child succumbed to cardiac arrest.

Case 6

A seven-year-old female child developed Stevens-Johnson Syndrome (SJS)/Toxic Epidermal Necrolysis (TEN) in response to Cefixime/Gentamicin, which were administered for fever and abdominal pain at a local hospital. Four hours after receiving the injection, the child developed erythema and skin peeling, involving 100% of the Body Surface Area (BSA) (Table/Fig 8). The SCORTEN value was four. The patient was treated with intramuscular injection of Dexamethasone 8 mg, along with intravenous Immunoglobulin (IVIG) calculated at 2 g/kg. Unfortunately, despite the treatment, the child could not be revived.

In summary, injection Etanercept was found to be a life-saving drug, reducing the time for re-epithelialisation to less than a week and resulting in a shorter hospital stay (Table/Fig 9),(Table/Fig 10),(Table/Fig 11).


In this case series of six patients with Toxic Epidermal Necrolysis (TEN), three patients were treated with a single dose of injection Etanercept 50 mg. These patients showed healing and faster re-epithelialisation without severe side effects (Table/Fig 12),(Table/Fig 13). Previous findings reporting increased levels of TNF-alpha in skin biopsy specimens (1) or in blister fluid and serum (2) of TEN patients have supported the use of biologic therapy with anti-TNF-alpha monoclonal antibodies (infliximab) or soluble fusion proteins binding to human TNF-alpha (etanercept). The present case series further confirms the reported effectiveness of anti-TNF-alpha drugs (1),(3),(4).

It is important to note that these case reports do not constitute randomised controlled studies, and the overall number of patients is still small. Nonetheless, the outcomes are more favourable compared to “standard” approaches. The pathogenesis of TEN is still not fully understood. However, observations such as faster and more severe the increased risk of developing TEN in patients with certain HLA haplotypes when exposed to certain drugs indicate a role for T-cell mediated immune responses in its pathogenesis (5),(6).

The immune cell infiltration, including cytotoxic T-cells, found in the skin of TEN patients seems insufficient to induce massive keratinocyte apoptosis, suggesting that some cytotoxic proteins and/or cytokines may amplify the process. Upregulation of FasL expression on the surface of keratinocytes from TEN patients has been shown to induce keratinocyte apoptosis through engagement with constitutively expressed Fas (6),(7). According to the proposed mechanism, an inducible Nitric Oxide Synthase (iNOS)/nitric oxide/FasL pathway may link immune activation and widespread keratinocyte apoptosis in TEN. Activated T-cells secrete TNF-alpha recurrence of TEN upon re-exposure to the same offending drug, the presence of drug-specific T-cells in the skin of TEN patients, and and interferon-gamma, which can induce iNOS expression and nitric oxide production by keratinocytes, leading to FasL upregulation and Fas-mediated keratinocyte apoptosis. Etanercept therapy acts by blocking this inflammatory pathway through TNF-alpha inhibition.

It is worth noting that in addition to TNF-alpha, etanercept also blocks lymphotoxin alpha (LFT-alpha), which has been reported to play a role in the pathogenesis of graft-versus-host disease, a condition that shares clinical, histologic, and pathogenetic similarities with TEN. This suggests that TNF-alpha could play a role in TEN pathogenesis, and its blockage, along with that of LFT-alpha, may contribute to the robust and rapid therapeutic effect of etanercept observed in the patients of this study. Paradisi A et al., published a case series of 10 cases of TEN treated with a single dose of etanercept, reporting that all patients responded to treatment with complete re-epithelialisation achieved without side effects, with a median time to heal of 8.5 days (8). Wang CW et al., concluded that TNF-alpha inhibitors are effective for the treatment of Cytotoxic T lymphocyte (CTL)-mediated Severe Cutaneous Adverse Reactions (SCARs) (9).


As TNF-alpha has been demonstrated within the blister fluid, serum, and on the keratinocyte cell surface, and TNF-alpha upregulates iNOS in keratinocytes, consequently leading to FasL-mediated cell death through the perforin-granzyme B pathway as the final terminal event, the authors found that the duration of hospital stay was reduced, and steroid-related complications were eliminated with the use of injection Etanercept. Morbidity and mortality related to adverse drug reactions were greatly reduced, and the treatment outcomes were impressive. Etanercept is a wonderful tool in the dermatologist’s armamentarium to minimise deaths and promote faster re-epithelialisation with minimal side-effects.


Hunger RE, Hunziker T, Buettiker U, Braathen LR, Yawalkar N. Rapid resolution of toxic epidermal necrolysis with anti-TNF-α treatment. J Allergy Clin Immunol. 2005;116(4):923-24. [crossref][PubMed]
Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol. 2002;146(4):707-09. Doi: 10.1046/j.1365-2133.2002.46833.x. [crossref][PubMed]
Wojtkiewicz A, Wysocki M, Fortuna J, Chrupek M, Matczuk M, Koltan A. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol. 2008;88(4):420-21. Doi: 10.2340/00015555-0462. [crossref][PubMed]
Kreft B, Wohlrab J, Bramsiepe I, Eismann R, Winkler M, Marsch WC. Etoricoxib- induced toxic epidermal necrolysis: Successful treatment with infliximab. J Dermatol. 2010;37(10):904-06. Doi:10.1111/j.1346-8138.2010.00893. [crossref][PubMed]
Paquet P, Paquet F, Al Saleh W, Reper P, Vanderkelen A, Piérard GE. Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. Am J Dermatopathol. 2000;22(5):413-17. Doi:10.1097/00000372-200010000-00005. [crossref][PubMed]
Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109(1):155-61. Doi:10.1067/ mai.2002.120563. [crossref][PubMed]
Sadhigha A. Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis/toxic epidermal necrolysis: Definition of a new model based on translational research. Int J Dermatol. 2009;48(8):913-14. [crossref][PubMed]
Paradisi A, Abeni D, Bergamo F, Ricci F, Didona D, Didona B. Etanercept therapy for toxic epidermal necrolysis. J Am Acad Dermatol. 2014;71(2):278-83. [crossref][PubMed]
Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, et al. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985-96.[crossref][PubMed]

DOI and Others

DOI: 10.7860/JCDR/2023/62912.18615

Date of Submission: Jan 15, 2023
Date of Peer Review: Feb 25, 2023
Date of Acceptance: Jul 07, 2023
Date of Publishing: Nov 01, 2023

• Financial or Other Competing Interests: None
• Was informed consent obtained from the subjects involved in the study? Yes
• For any images presented appropriate consent has been obtained from the subjects. Yes

• Plagiarism X-checker: Jan 17, 2023
• Manual Googling: Mar 17, 2023
• iThenticate Software: Jul 05, 2023 (10%)

ETYMOLOGY: Author Origin


JCDR is now Monthly and more widely Indexed .
  • Emerging Sources Citation Index (Web of Science, thomsonreuters)
  • Index Copernicus ICV 2017: 134.54
  • Academic Search Complete Database
  • Directory of Open Access Journals (DOAJ)
  • Embase
  • EBSCOhost
  • Google Scholar
  • HINARI Access to Research in Health Programme
  • Indian Science Abstracts (ISA)
  • Journal seek Database
  • Google
  • Popline (reproductive health literature)